were only collected from EHRs of patients who had an ECG as part of a medical evaluation; ECG data prior to medication prescription were not recorded. In addition, there were no standardized criteria for obtaining an ECG within the 14-90-day period after starting a medication, introducing selection bias. Interestingly, there was an actual decrease in the mean QTc with citalopram dose increase from 20 to 40 mg, likely indicating confounding variables or a lack of power in the study. Implication for toxicologists: Many pharmaceuticals affect the QT interval, which is a surrogate for the risk of torsades de pointes. This study identified commonly used antidepressants and the possible effect on QT interval associated with specific changes in their dosing. It did not, however, contribute to our understanding on the cardiac risks of placing patients on these medications. Background: Despite established efficacy and generally good safety profiles of pharmacological treatments for attention deficit hyperactivity disorder (ADHD), concerns remain for cardiovascular adverse events, including sudden cardiac death. FDA-approved medications for ADHD include atomoxetine, alpha 2 -adrenergic agonists, and CNS stimulants (i.e., amphetamine-related) compounds. Research question: Is there an increased risk of serious cardiovascular problems, including QTc interval prolongation and sudden cardiac death in patients prescribed with medications for ADHD? Methods: This was a systematic review of published literature concerning the use of ADHD medications and serious cardiovascular problems, including sudden cardiac death, stroke, arrhythmias and prolonged QTc. Relevant databases (PubMed, EMBASE, and PsychINFO) were searched using appropriate medical subject headings and keywords. A total of 584 articles were identified. After removing unrelated and duplicate publications, a total of 81 were reviewed. These included clinical research and retrospective or prospective population-based studies of children, adolescents, and/or adults. Selected data concerning toxicity and overdoses were included.
Results:
In controlled and open-label extension studies, use of methylphenidate or amphetamine for ADHD in both children and adults was associated with statistically significant (though minimal) increases in mean systolic blood pressure (<5 mmHg), mean diastolic blood pressure (<5 mmHg), and mean heart rate (Hr; <5 bpm). There was no strong evidence of QTc prolongation in children. In adults, one study observed a QTc increase of 7.2 ms at 24 months when taking mixed amphetamine salts. There were several rare cardiovascular adverse events reported with methylphenidate and mixed amphetamine salts; however, most of these were in case reports or studies with confounding variables. Studies on lisdexamfetamine did not find significant changes in blood pressure (Bp) and only minimal changes in Hr (<5 bpm). Only one case-control study found an association between use of stimulants for ADHD and sudden unexplained death. This study involved significant limitations and methodological confounders.
Since atomoxetine undergoes CYP2D6 metabolism, several studies focused on comparing poor and extensive metabolizers. Poor metabolizers were found to have a slight but statistically significant increase in Hr and Bp compared to extensive metabolizers. Large clinical trials and population studies did not find a difference in QTc interval length, nor were there reports of serious cardiovascular adverse events, sudden cardiac death, or arrhythmias.
The alpha 2 -adrenergic agonists, clonidine and guanfacine, were associated with minimally decreased Bp (<5 mmHg) and Hr. Overall, there was a minimal effect on QTc duration.
In several population-based studies, the rates of sudden death or serious cardiovascular events in patients taking medications for ADHD were no different than the general population. Other studies have found a potential association between ADHD and sudden unexplained death, independent of pharmacological treatment and possibly due to ADHDrelated comorbidities. Conclusion: Serious cardiovascular events and sudden unexplained cardiac deaths related to ADHD medications are very rare. There does not seem to be an association between ADHD medication, at therapeutic doses, and QTc prolongation. There are small but clinically insignificant increases in blood pressure and heart rate associated with use of stimulants and atomoxetine. There is no evidence that obtaining a pretreatment ECG, in asymptomatic patients, is useful in identifying those at risk for adverse cardiovascular effects. Critique: This study was a comprehensive review of the literature regarding the occurrence of cardiovascular events associated with the use of ADHD medications. It also provided a concise pharmacokinetic and pharmacodynamic review of the medications used to treat ADHD. Weaknesses included use of the broad outcome "cardiovascular adverse events" and the inclusion of various study designs which limited the comparison of findings. The clinical significance of small increases in blood pressure and heart rate, and optimal management of these effects, is unclear from the information presented. The impact of personal or family history of cardiovascular disease on the occurrence of adverse effects from ADHD medications was not addressed. Implication for toxicologists: This article provides toxicologists with a concise review of the pharmacodynamics, and potential cardiovascular side effects, of ADHD medications. It can be used to educate patients and their families on the incidence of cardiovascular effects seen with these medications.
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Background: Opioid overdose is a leading cause of accidental deaths in the USA. Research on the distribution of naloxone to laypersons and drug users has shown a reduction in overdose death rates. Other studies have found that drug users can be trained to identify and respond to overdose, including effective use of naloxone. There are little data on whether distribution of naloxone "kits" is cost-effective. Research question: Is the distribution of naloxone to heroin users, for witnessed overdoses, cost-effective and associated with decreased mortality? Methods: A computer-based model was developed to analyze the effectiveness of distributing naloxone to heroin users. The model used probability and deterministic analyses based on current epidemiological data of heroin use in the USA. Various parameters were factored into the model and included the following: probability of someone using the distributed naloxone for a witnessed overdose, likelihood of involving emergency medical services and other health care resources, proportion of heroin users who survive overdose, annual death rates for heroin users, rates of heroin discontinuation and relapse, and cost of naloxone distribution and health care resources. These parameters were used to estimate costs, quality-adjusted life-years (QALY) gained, and to calculate incremental cost-effectiveness ratios (ICERs; incremental cost per QALY gained). Several parameters, including estimates of overdose, mortality, naloxone use, and cessation of drug use, were adjusted to predetermined extreme values to help minimize uncertainty. Several assumptions were involved, including an ICER less than $50,000 being "traditionally considered cost-effective." Results: In the probabilistic analysis, distribution of naloxone to 20 % of heroin users resulted in a 6 % decrease in overdose deaths. One death would be prevented for every 227 naloxone kits distributed (number needed to treat; CI 71-716). In the deterministic analyses, 6 % of overdose deaths were prevented, and the number needed to treat was 164. Naloxone distribution was cost-effective in a variety of analyses. The ICER for QALY gained ranged from $438 to (in the worst case scenario) $14,000. Cost-effectiveness was sensitive to the cost and efficacy of lay-administered naloxone, but relatively insensitive to the breadth of naloxone distribution, rates of overdose and other drug-related deaths, rates of abstinence and relapse, and absolute cost of medical services. Conclusion: Based on a computer model, naloxone distribution to heroin users reduced overdose deaths by approximately 6 %. The number needed to treat ranged from 164 to 227, depending on the parameters. This practice appears cost-effective even under conservative assumptions. Critique: The model relied on policy standards, survey data, and epidemiological information to determine outcomes. If these were incorrect, the calculated probabilities of specific outcomes are inaccurate, limiting the validity of results. Policy standards for cost-effectiveness are not necessarily the same as societal standards. Determining other cost parameters would be valuable, such as the absolute cost of naloxone distribution compared to the cost of medical care for overdose-related complications. Implication for toxicologists: Though a universally accepted definition of cost-effectiveness was not evaluated, this study suggests that naloxone distribution is effective for reducing overdose deaths.
